Nervonik

Nervonik operates in medical devices and neuromodulation, focusing on an opioid-free peripheral nerve stimulation system for chronic neuropathic pain. Its stated differentiation is the combination of implantable nerve-stimulation devices, an external wearable for wireless power transfer and data collection, and digital controls for therapy adjustment and clinical monitoring. The company also emphasizes applications in high-motion settings, an important design consideration for peripheral nerve stimulation. A $52.5 million Series B, first-in-human feasibility results announced on Jun 16, 2026, and a clinical advisory group with pain-medicine expertise indicate growing development resources. However, regulatory status, reimbursement strategy, commercial launches, and comparative clinical performance are not sufficiently documented to assess market share or category leadership.

Nervonik’s trajectory shows a progression from company formation in 2020 to clinical-stage neuromodulation development. The company recorded a seed round dated Jan 1, 2021, followed by a $13 million Series A on Mar 4, 2025 led by U.S. Venture Partners. Its largest financing event came on Apr 27, 2026, when Nervonik raised $52.5 million in Series B funding led by Amzak Health Investors. The step-up in financing coincided with a shift toward clinical validation: on Jun 16, 2026, Nervonik reported completing a first-in-human feasibility study involving nerve sensing during peripheral nerve stimulation across multiple anatomical targets. The study’s Top Abstract selection by the American Society of Pain and Neuroscience added external recognition to that milestone. Leadership expansion in July 2026, including Rob DiTota, Dan Brounstein, and Patrick Martin, suggests the company is adding operating capacity as development advances. Its product portfolio spans implantable PNS devices, a wireless power-transfer wearable, and a digital app control system. The main inflection points are therefore the 2025 Series A, 2026 Series B, first-in-human study completion, and leadership build-out. Commercial launch timing and regulatory milestones remain unclear.